title: Tryptanthrin-loaded nanoparticles for delivery into cultured human breast cancer cells, MCF7: the effects of solid lipid/liquid lipid ratios in the inner core.
abstract: Tryptanthrin is an ancient medicine which recently was also found to have a function of downregulating multidrug resistance (MDR). However, tryptanthrin is insoluble in water, which limits its availability for delivery into cancer cells. There is a need to improve delivery systems to increase the inhibition of MDR. The aim of this study was to employ nanoparticles encapsulating tryptanthrin to improve the delivery and promote the sustained release of this drug. The approach was to encapsulate tryptanthrin in various nanoparticles, including solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid emulsions (LEs). We compared the particle size and zeta potential of these nanoparticles, and evaluated the partitioning behavior of tryptanthrin in them. We also determined the release kinetics of tryptanthrin from these nanoparticles. Moreover, cellular cytotoxicity toward and uptake of tryptanthrin-loaded nanoparticles by human breast cancer cells were determined. We found that the mean particle size of NLCs was lower, and the partition coefficient was higher than those of SLNs, and an increased tryptanthrin release rate was found with the NLC delivery system. NLCs achieved the sustained release of tryptanthrin without an initial burst. In particular, the NLC-C formulation, composed of a mixture of Compritol and squalene as the core materials, showed the highest release rate and cytotoxic effect. Confocal laser scanning microscopic images confirmed drug internalization into cells which enhanced the endocytosis of the particles. These results suggested that NLCs can potentially be exploited as a drug carrier for topical or intravenous use in the future.
authors.affiliation: Department of Biotechnology, Yuanpei University, Hsinchu, Taiwan.
authors.forename: Yi-Ping
authors.initials: YP
authors.lastname: Fang
authors.forename: Yin-Ku
authors.initials: YK
authors.lastname: Lin
authors.forename: Yu-Han
authors.initials: YH
authors.lastname: Su
authors.forename: Jia-You
authors.initials: JY
authors.lastname: Fang
mesh_terms: D001943:Breast Neoplasms; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D006801:Humans; D008055:Lipids / Q000008:administration & dosage* / Q000737:chemistry; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D011799:Quinazolines / Q000008:administration & dosage* / Q000737:chemistry; D012995:Solubility / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D008055:Lipids; D011799:Quinazolines; C046243:tryptanthrine